Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB15 versus Eylea in neovascular age-related macular degeneration
2019-003883-28Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sonidegib and aflibercept in exudative macular degeneration (2 arms), sponsored by Samsung Bioepis. Primary endpoint: Change from baseline in best corrected visual acuity at Week 8. Started Mar 2020; status: completed.
02
Drugs
sonidegibaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-003883-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003883-28.